VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

Inclusion Criteria:

• Patient having received tandem transplants with high-dose melphalan and autologous PBSCT within 3-6 months prior to inclusion into this protocol
• Patients with measurable minimal residual disease (very good partial remission [VGPR]) or patients in partial remission (PR) or patients with stable disease (SD) at the time of inclusion in the study
• Patient must agree to participate in the study.
• Patient agrees to use an appropriate method of contraception.
• Willingness and ability to comply with the study protocol for the duration of the study

Exclusion Criteria:

• Patient showing signs of disease progression
• Patient has a platelet count < 100 x 10^9/L within 14 days before enrollment.
• Patient has an absolute neutrophil count < 1.0 x 10^9/L within 14 days before enrollment.
• Patient has a calculated or measured creatinine clearance < 30 mL/minute within 14 days before enrollment.
• Patient has >= Grade 2 peripheral neuropathy within 14 days before enrollment.
• Patient has hypersensitivity to bortezomib, boron, or mannitol.
• Patient has received prior treatment with bortezomib
• Patient is pregnant or nursing
• Patient has received other investigational drugs within 14 days before enrollment
• Patient has progressive disease
• Patient has a Karnofsky performance status < 60%
• Patient has a life expectancy of < 3 months
• Patient has received disease modifying agents following autologous stem cell transplantation other than aminobisphosphonates such as interferon-alpha or glucocorticosteroids
• Patient currently enrolled in another clinical research study and/or receiving an investigational reagent for any reason.